CMXC - Cell MedX Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
0.2250
0.0000 (0.00%)
At close: 11:46AM EDT
Stock chart is not supported by your current browser
Previous Close0.2250
Open0.2000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0000 - 0.0000
52 Week Range
Volume9,330
Avg. Volume4,162
Market Cap9.964M
Beta (3Y Monthly)-0.69
PE Ratio (TTM)N/A
EPS (TTM)-0.0210
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Newsfilelast month

    Cell MedX Corp. Provides an Update on Progress Toward US Premarket Clearance and Clarifies its eBalance Certification

    Carson City, Nevada--(Newsfile Corp. - February 12, 2019) - Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"), an early development stage biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness is pleased to announce significant progress toward obtaining premarket clearance in the US for its eBalance device. The eBalance device is not yet available for sale in the US.The Company has been ...

  • Newsfile3 months ago

    Cell MedX Corp. Enters into Credit Line Agreement and Issues Warrants

    Carson City, Nevada--(Newsfile Corp. - December 31, 2018) - Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announces that on December 27, 2018, the Company entered into an Agreement with Mr. Richard Jeffs (the "Lender"), the Company's major shareholder (the "Agreement"), for an unsecured line of credit of up to ...

  • Newsfile3 months ago

    Cell MedX Corp. Manufactures eBalance Devices in Canada

    Carson City, Nevada--(Newsfile Corp. - December 12, 2018) -  Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness is pleased to announce that it has successfully completed its first 100 Canadian manufactured eBalance devices.Upon receiving its Certificate of Conformity, qualifying the eBalance devices as Class A (professional use) and Class B ...

  • Newsfile4 months ago

    Cell MedX Corp. Receives Safety and Electrical Certifications for the eBalance Pro Device

    Carson City, Nevada--(Newsfile Corp. - December 4, 2018) -  Cell MedX Corp. (OTCQB: CMXC), Cell MedX Corp. ("Cell MedX" or the "Company"), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announced today that the Company received electrical and safety certification for the Company's eBalance Pro device (the "Device"). The Company has received a Certificate of Conformity, from LabTest Certification Inc., ...

  • Newsfile6 months ago

    Cell MedX Corp Signs Letter of Intent for Worldwide Distribution Rights and Enters into Royalty Agreement Contracts

    Carson City, Nevada--(Newsfile Corp. - September 14, 2018) - Cell MedX Corp. (OTCQB: CMXC), Cell MedX Corp. ("Cell MedX" or the "Company"), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announced today that on September 10, 2018, the Company entered into a non-binding letter of intent (the "LOI") with Live Current Media, Inc. ("LIVC"), an arms-length party, for worldwide distribution rights of ...

  • Newsfile11 months ago

    Dr. Terrance Owen Resigns as CEO of Cell MedX Corp

    Carson City, Nevada--(Newsfile Corp. - May 7, 2018) - Cell MedX Corp. (OTCQB: CMXC), Cell MedX Corp. ("Cell MedX" or the "Company"), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announced today that, effective April 30, 2018, Dr. Terrance Owen resigned from his management and directorship positions with Cell MedX. The resignation of Dr. Owen was not due to ...

  • Newsfilelast year

    Cell MedX Corp. Appoints Dr. George Adams as Director

    Carson City, Nevada--(Newsfile Corp. - March 26, 2018) - Cell MedX Corp. (OTCQB: CMXC) (9CX: MUN), ("Cell MedX" or the "Company"), an early-stage biotech company focusing on the discovery, development and commercialization of products that promote general wellness, is pleased to announce that it has appointed Dr. George Adams to the Board of Directors. "Cell MedX has just completed a clinical trial where it has demonstrated a significant lowering of blood pressure in patients ...